Chemaphor Inc.

Chemaphor Inc.

April 24, 2008 16:00 ET

Chemaphor Announces Election of New Director

OTTAWA, ONTARIO--(Marketwire - April 24, 2008) - Chemaphor Inc. (TSX VENTURE:CFR) today announced that Mr. Jacques Brault was elected as a new member of Chemaphor's board of directors at the annual and general meeting of shareholders held on April 17, 2008. The existing members of Chemaphor's board members were re-elected as well.

Jacques Brault is a businessman with an extensive background in the food service industry. He is currently president and majority shareholder of several financial holding companies. He is also the CEO and owner of a commercial real estate-related company. Mr. Brault has held several key positions in the financial industry.

"We are pleased to have Jacques Brault join our board of directors." said Dr. Graham Burton, President and CEO of Chemaphor. "Mr. Brault's business and financial experience bring valuable complementary strengths to the board that will be important as the company moves forward toward the commercialization of its first product"

Chemaphor also announced pursuant to the requirements of the TSX Venture Exchange, that it has granted options to purchase 140,000 common shares of Chemaphor to directors and officers. The stock options were granted pursuant to the terms of Chemaphor's stock option plan and are exercisable at $0.22 per share. These grants form part of a total remuneration package. Stock option grants are subject to necessary regulatory approvals.

About Chemaphor Inc.

Chemaphor Inc. ( uses its core expertise in organic chemistry to develop premium products for the animal health, skin care cosmetics, pharmaceutical and specialty chemical markets. The Company's focus is on two proprietary products, a non pharmaceutical product OxBC and a lead cancer drug compound OCL-1. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by finding recognized partners to commercialize its products in multiple, large markets.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information